جست‌وجوی استاد و پژوهشگر

Chloe E. Atreyaمشاهده پروفایل

استاد

• Gastrointestinal Cancer
• Colorectal Cancer
• Tumor Genetics
• +۵ مورد دیگر

Dr. Chloe E. Atreya is a Professor of Medical Oncology at the University of California San Francisco (UCSF) School of Medicine, specializing in gastrointestinal and colorectal cancers at the UCSF Helen Diller Comprehensive Cancer Center. She co-directs the Integrative Oncology Program and Research Hub, focusing on tumor genetics, personalized therapy, and gut microbiome interactions to improve patient outcomes. Her research integrates clinical trials with molecular analysis to overcome treatment resistance. Dr. Atreya's educational background includes: BA in Molecular Biology with Visual Art Certificate from Princeton University (1998) PhD in Pharmacology and MD from Yale University (2004, 2005) Internal Medicine residency at University of Washington (2008) Medical Oncology fellowship and Advanced Clinical Research Training at UCSF (2010, 2014) Clinical Fellowship in Integrative Medicine (2018-2019) Her research spans tumor genetics, gut microbiome interactions, and integrative oncology approaches. Recent publications reveal strong focus on microbiome-mediated drug metabolism, precision medicine strategies for KRAS/BRAF-mutant cancers, and patient-centered interventions for cancer survivors. She leads multiple NIH-funded projects examining resistance mechanisms and nutritional interventions. Dr. Atreya has received significant recognition including: ASCO Young Investigator Award (2011) Multiple UCSF research awards (2012-2017) Sandler Program Breakthrough Award (2022) ASCO-Integrative Oncology Clinical Guidelines leadership As Principal Investigator on multiple NIH grants including R01CA229447 and R37CA266549, she directs translational research programs examining kinome-guided targeting and KRAS inhibition resistance. Her work bridges basic science with clinical applications through the Integrative Oncology Research Hub, developing evidence-based complementary approaches for symptom management and quality of life improvement.

Andrew K. Godwinمشاهده پروفایل

استاد

• Translational Research
• Precision Medicine
• Ovarian Cancer
• +۷ مورد دیگر

Andrew K. Godwin, Ph.D., is a Chancellor’s Distinguished Chair in Biomedical Sciences Endowed Professor, Division Director of Genomic Diagnostics, and Director of Molecular Oncology at the University of Kansas Medical Center (KUMC). He is Deputy Director of the NCI-Designated KU Comprehensive Cancer Center and Founding Director of the Kansas Institute for Precision Medicine, the Biospecimen Shared Resource, and the Center for Genomic Services and Health Equity. With over 550 peer-reviewed publications and an h-index of 144, his work bridges basic and clinical sciences to advance precision oncology. Chancellor’s Distinguished Chair in Biomedical Sciences Division Director, Genomic Diagnostics Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Director, Biospecimen Shared Resource Director, Center for Genomic Services and Health Equity Dr. Godwin's research focuses on early cancer detection , liquid biopsies , and molecular therapeutics . His laboratory investigates extracellular vesicle biology , biosample ascertainment , and companion diagnostics to improve patient outcomes in ovarian cancer , breast cancer , and Ewing sarcoma . Recent work emphasizes multi-omics approaches for biomarker validation and therapeutic development . His laboratory has produced groundbreaking studies on AKT2 activation in ovarian cancer , KRAS mutations in EGFR-targeted therapy , and circulating tumor cell diagnostics . Current research trends integrate spatial transcriptomics , mitochondrial DNA mutations , and immune microenvironment profiling across cancer types. Scientific honors include: Dolph C. Simons, Sr. Higuchi Award (2020) KU Mentoring Awards (2021, 2024) NIH/NIGMS COBRE Grant ($24M total) CELLSEARCH® Clinical Validation Leadership Dr. Godwin mentors over 150 trainees across career stages and leads KUMC's Clinical Molecular Oncology Laboratory (CMOL) and Biomarker Discovery Lab (BDL) , advancing team science and translational research infrastructure.

• Genetics
• Molecular Biology
• Bioinformatics
• +۴ مورد دیگر

Sevinç AKÇAY is a Lecturer at the Department of Molecular Biology and Genetics in the Faculty of Arts and Sciences at Kırşehir Ahi Evran University , Turkey. She holds a PhD (2016) and MSc (2012) in Molecular Biology from the University of Pittsburgh , and a BSc (2008) in Biology from Ankara University . Research Focus: Genetics, Molecular Biology, and Bioinformatics, with emphasis on elastin gene mutations , cancer genomics , and computational disease modeling . Key Projects: Investigated Tiochlorosid and Malathion effects on cancer cell lines; led studies on epigenetic mechanisms and ferroptosis in cancer . Teaching: Offers courses in Genetic Engineering , Epigenetics , and CRISPR Technologies at both undergraduate and graduate levels. Collaborations: Works with international researchers like Zsolt Urban (University of Pittsburgh) and Emine Güven (Düzce University) on computational biology and genetic disorders.

Stephan Reuterمشاهده پروفایل

استاد

• Plasma Physics
• Plasma Medicine
• Ultrafast Laser Spectroscopy
• +۴ مورد دیگر

Stephan Reuter is a Full Professor in the Department of Engineering Physics at Polytechnique Montréal , holding the TransMedTech Research Chair in Plasma Medicine . His work bridges plasma physics, biomedicine, and environmental technology through advanced diagnostics and interdisciplinary applications. Education: Dipl. Phys.-Ing. (Master in Engineering Physics), Dipl. Phys. (M.Sc. in Physics), Dr. rer. nat. (PhD) Affiliations: TransMedTech Institute, Institute of Biomedical Engineering, Alexander von Humboldt Foundation Alumnus Research Interests: Non-thermal plasma physics, plasma medicine, ultrafast laser diagnostics, plasma-liquid interactions, environmental remediation His 15 most recent publications (2022-2025) focus on cold atmospheric plasma jets for cancer therapy, agricultural sustainability, and microfluidic integration. These works span Plasma Medicine , Environmental Technology , and Advanced Diagnostics , with specific subfields like 3D tumor modeling, reactive oxygen species analysis, and precision plasma dosimetry. Scientific Leadership : Feodor Lynen Research Fellow (Princeton University, 2017-2018) Co-founder of Leibniz Institute's Plasma Medicine Group Editorial contributor to Plasma Sources Science and Technology Research Impact : Over 98 peer-reviewed journal articles Keynote speaker at ISPC26 (2025) Major grants: $3.4M for greenhouse plasma technology (2024), $1M NFRF Exploration Grant (2021) Labs & Collaborations : Polytechnique Montréal Plasma Biophysics Lab TransMedTech Institute International collaborations: Leibniz Institute (Germany), Queens University (UK), Lublin University (Poland)

Chad Brennerمشاهده پروفایل

دانشیار

• Cancer Biology
• Genomics
• Precision Medicine
• +۶ مورد دیگر

Chad Brenner, Ph.D. serves as Associate Professor of Otolaryngology-Head and Neck Surgery and Pharmacology at the University of Michigan Medical School, where he also directs the CMB Program. His research focuses on genomic biomarker discovery and therapeutic resistance mechanisms in head and neck cancers, utilizing next-generation sequencing and high-throughput functional screening approaches. Dr. Brenner's primary research interests span Cancer Biology, Genomics, Precision Medicine, and Molecular Biology, with specific emphasis on HPV-related cancers, liquid biopsy development, and therapeutic resistance. His laboratory employs genomics-driven clinical trials and patient-derived xenograft models to advance targeted therapies and understand resistance mechanisms in head and neck squamous cell carcinoma. Analysis of his 15 most recent publications (2023-2025) reveals dominant themes in HPV-positive oropharyngeal cancer research, circulating tumor DNA (ctDNA) applications, tumor microenvironment characterization, and health disparities. Key methodologies include next-generation sequencing, liquid biopsy validation, and integration of imaging biomarkers with molecular data for treatment response prediction. Scientific Awards No scientific awards were documented in the provided source material. Advising and grant activities are not explicitly detailed in available information, though his CMB Program Director role suggests mentorship responsibilities. The source indicates student involvement through the CMB program but provides no specific advisee names or grant funding details. Laboratory operations focus on genomic analysis of head and neck cancers, with specialized expertise in HPV ctDNA assay development, tumor hypoxia studies, and functional screening for therapeutic target identification. The lab maintains strong clinical translation focus through ongoing participation in phase II immuno-chemoradiation trials and biomarker validation studies.

• Sarcoma Research
• Developmental Therapeutics
• Gastrointestinal Stromal Tumors (GIST)
• +۴ مورد دیگر

Dr. George D. Demetri is a Professor of Medicine at Harvard Medical School, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center. He serves as Executive Director for Clinical and Translational Research at the Ludwig Institute for Cancer Research and holds the Quick Family Chair in Medical Oncology. His clinical focus centers on bone sarcomas, gastrointestinal stromal tumors (GIST), and soft tissue sarcomas. Dr. Demetri's research interests span molecular targeted agents and signal transduction inhibitors for sarcoma treatment. His groundbreaking work established the foundation for using tyrosine kinase inhibitors as effective therapies for GIST, leading to FDA approval of imatinib mesylate (Gleevec). His research team pioneered differentiation therapy for liposarcomas targeting PPAR-gamma and developed novel agents like ET-743 derived from marine organisms. His work demonstrates how understanding sarcoma biology can translate into targeted treatments that significantly improve patient outcomes. Analysis of Dr. Demetri's recent publications reveals a strong focus on immunotherapy approaches for sarcomas, particularly T-cell therapies targeting NY-ESO-1, and continued innovation in molecularly targeted treatments. His research spans rare sarcoma subtypes, biomarker identification, and real-world evidence generation for oncology drug development. The publications consistently emphasize precision medicine approaches tailored to specific molecular alterations in sarcomas. Focused Giving Program Award, Johnson and Johnson Foundation (1993) Emil J. Freireich Award in Clinical Cancer Research (2002) Claire W. and Richard P. Morse Research Award (2005) Dr. Demetri leads a multidisciplinary research team that includes dedicated representatives from surgical oncology, radiation oncology, pathology, and other clinical arenas working closely with laboratory investigators. His work has secured significant funding for sarcoma research, particularly through the Ludwig Institute for Cancer Research. His leadership has established Dana-Farber as a global center for sarcoma treatment and research, with numerous clinical trials evaluating novel therapeutic approaches for these rare cancers. As Director of the Sarcoma Center at Dana-Farber, Dr. Demetri oversees a comprehensive program that brings together experts across multiple disciplines to develop innovative treatments for sarcoma patients. His laboratory research focuses on translating basic biological discoveries into novel therapeutic approaches, with particular emphasis on signal transduction pathways in sarcomas. The center maintains strong collaborations with other major cancer centers globally to advance sarcoma research and treatment.

• Acute Lymphoblastic Leukemia
• Pediatric Brain Tumors
• Genetic Heterogeneity
• +۵ مورد دیگر

Stephen E. Sallan, MD , is a Professor of Pediatrics at Harvard Medical School and a Physician at Dana-Farber Cancer Institute and Children's Hospital . His career spans over five decades in pediatric hematology/oncology , with a focus on acute lymphoblastic leukemia (ALL) and pediatric brain tumors . Education : MD, Wayne State University School of Medicine (1967) Residencies : Boston Floating Hospital (1968), Children's Hospital of Philadelphia (1969), Hospital for Sick Children, London (1970) Fellowship : Pediatric Oncology, Children's Hospital/DFCI (1972) Leadership Roles : Chief of Staff (1995), Chairman of Medical Staff Executive Committee (1995), Chief of Staff Emeritus (2012) Dr. Sallan's research integrates genetic heterogeneity , disease recurrence , and drug resistance in ALL, with efforts to develop targeted therapies like tumor vaccines and antiangiogenesis agents. His work addresses long-term treatment toxicities (cardiac, skeletal, neurocognitive), particularly in survivors of childhood cancers. His 15 most recent publications (2024–2018) demonstrate ongoing engagement with pharmacogenomics, thrombosis risk models, dietary interventions, and molecular markers in brain tumors. Key subfields include TRK-C in medulloblastoma , asparaginase complications , and DFCI ALL Consortium Protocols . Scientific Awards : Distinguished Alumni Award, Wayne State University School of Medicine (1997) James Carreras Prize for International Pediatrician of the Year (1987) As a leader in pediatric leukemia research , Dr. Sallan has shaped treatment protocols that minimize late effects while improving survival. He collaborates with multidisciplinary teams in neuro-oncology and pharmacogenomics, maintaining active roles in clinical trials and laboratory investigations.

Peter Murrayمشاهده پروفایل

استاد

• Immunology
• Macrophage biology
• Immune regulation
• +۴ مورد دیگر

Professor Dr. Peter Murray is a leading immunologist and permanent group leader of the "Immune Regulation" research group at the Max Planck Institute of Biochemistry in Martinsried, Germany. Since 2018, he has also served as an Honorary Professor at the Technical University of Munich (TUM). His research delves into the intricate mechanisms governing immune system decision-making, with a particular focus on macrophage biology, amino acid metabolism, and immunometabolism in health and disease. Education and Career: Ph.D., The Walter and Eliza Hall Institute of Medical Research, University of Melbourne (1988–1991) B.Sc. (Hons), Monash University, Melbourne (1984–1987) Post-Doctoral Fellow, Whitehead Institute & MIT (1991–1998) Assistant to Associate Member, St. Jude Children's Research Hospital (1998–2014) Group Leader (Permanent), Max Planck Institute of Biochemistry (2017–present) Honorary Professor, Technical University of Munich (2018–present) Research Interests: Professor Murray's work is centered on understanding how the immune system makes critical decisions, particularly how metabolic cues influence immune responses. His group investigates macrophage and T-cell interactions, amino acid metabolism in immune regulation, and the role of immunometabolism in diseases like cancer, autoimmunity, and chronic infections. The team employs innovative approaches, including spatial proteomics and iPSC-derived macrophage models, to uncover new biological principles and therapeutic targets. Scientific Awards and Honors: Elected to the American Academy of Microbiology (2015) St. Jude Children's Research Hospital Faculty Mentoring Award (2013) Elected Chair, American Society of Microbiology Division E (Immunology) (2012) The Hartwell Foundation Individual Biomedical Award (2010) C. J. Martin Fellow, NH&MRC Australia (1991–1994) Labs and Teams: Professor Murray leads the "Immune Regulation" research group at the Max Planck Institute of Biochemistry, a multidisciplinary team exploring the intersection of immunology and metabolism. The group collaborates extensively with international partners, including St. Jude Children's Research Hospital and various European research centers.

Rancoita Paola Maria Vittoriaمشاهده پروفایل

دانشیار

• Biostatistics
• Bioinformatics
• Survival Data Analysis
• +۶ مورد دیگر

Rancoita Paola Maria Vittoria is an Associate Professor of Medical Statistics (MED/01) at the Faculty of Medicine and Surgery, Vita-Salute San Raffaele University (UniSR), since 2022. She is actively involved in research activities at the University Center for Statistics for Biomedical Sciences (CUSSB) and serves on the Board of Directors of CUSSB (since 2016) and the Scientific Committee of CeNRI (Center for Nursing Research and Innovation, since 2016). She also participates in academic governance through multiple committees in the International MD Program (since 2020) and the Doctoral School in Public Health at the University of Milan-Bicocca (since 2020). Research Focus : Her work centers on developing and applying statistical methodologies in biostatistics and bioinformatics, including survival analysis with frailty models, repeated measures and clustered data analysis, genomic data integration via Bayesian regression, and stochastic geometry for angiogenesis image analysis. These techniques address clinical challenges like missing data handling and prognostic index identification. Academic Background : PhD in Mathematics and Statistics for Computational Sciences (2010), University of Milan Post-doctoral Researcher (2010-2011), IDSIA/IOSI Switzerland Research Fellow (2012-2013), Statistics SECS-S/01, Faculty of Psychology, UniSR Fixed-Term Researcher (2014-2021), Medical Statistics MED/01, UniSR Scientific Recognition : WHO Statistical Consultant (2022) Task Force Member, Stop TB Partnership (2020) ISBA Travel Award (2010) INdAM Fellowship (2004-2006) Leadership Roles : She served as Treasurer in the Italian Region of the International Biometric Society (2018-2021) and held leadership roles in Società Italiana di Statistica Medica ed Epidemiologia Clinica (2020-2021). Her teaching spans statistics, bioinformatics, and clinical data science across undergraduate and postgraduate programs at UniSR and Milan-Bicocca University.

• Cancer Biomarkers
• Tumor-Agnostic Research
• Precision Medicine
• +۶ مورد دیگر

Karin Jirström is a Professor at the Department of Therapeutic Pathology, Faculty of Medicine, Lund University. She leads the LUCC: Lund University Cancer Centre and serves as Vice Dean at the Faculty of Medicine. Her research focuses on tumor-agnostic cancer biomarker discovery and adaptive treatment strategies. Roles: Professor, Head of Division, Vice Dean, Principal Investigator, Supervisor Key Institutions: Lund University, Faculty of Medicine, Therapeutic Pathology, LUCC Research Interests: Jirström specializes in tumor-agnostic biomarkers, exploring tumor heterogeneity and clonal evolution to improve treatment for pancreatic, liver, biliary tract, and colorectal cancers. Her lab maintains extensive tissue microarray resources and conducts prospective clinical trials to optimize precision oncology. Recent Article Trends: Her 2024-2025 publications emphasize biomarker validation across multiple cancers, integrating epigenetics, machine learning, and tumor microenvironment dynamics. Key themes include adaptive therapy in colorectal cancer, chemoresistance in breast cancer, and liquid biopsy applications in PDAC. Supervision: She mentors students in projects like BILLIONSTARS (bile duct/liver cancer) and On-CALL (metastatic colorectal cancer), focusing on translational research and clinical collaborations. Labs & Collaborations: Jirström co-manages the Immunohistochemistry and Tissue Microarray Center Malmö, fostering interdisciplinary work with clinicians and researchers in cancer evolution and adaptive therapies.

Theodore G. Drivasمشاهده پروفایل

استادیار

• Genetic Medicine
• Genomics
• Human Genetics
• +۳ مورد دیگر

Theodore G. Drivas, MD, PhD is an Assistant Professor of Medicine at the University of Pennsylvania's Perelman School of Medicine. His research focuses on the genetic architecture of human disease, particularly examining interactions between common and rare genetic variants and their relationship to common and rare diseases. Academic Rank: Assistant Professor Institution: University of Pennsylvania School: Perelman School of Medicine Department: Department of Medicine Dr. Drivas's work spans multiple domains including: Genetic Medicine Genomics Human Genetics Precision Medicine Clinical Genetics Health Disparities Recent research trends show strong emphasis on: GWAS studies for inflammatory diseases like hidradenitis suppurativa Racial disparities in genetic testing access Polygenic risk score validation and implementation Multi-ethnic cancer susceptibility gene analysis Sex-specific genetic effects in cardiomyopathy Development of genomic implementation strategies

James Floryمشاهده پروفایل

دانشیار

• Pharmacoepidemiology
• Diabetes Management
• Clinical Trials
• +۳ مورد دیگر

James Flory is an Associate Professor of Population Health Sciences at Weill Cornell Medical College , Cornell University. With an MD and MSCE from the University of Pennsylvania (2009) and a BA from Columbia University (2002), he specializes in pharmacoepidemiology and clinical research related to diabetes management, drug safety, and healthcare policy. Education: M.D., University of Pennsylvania School of Medicine, 2009 M.S.C.E., University of Pennsylvania School of Medicine, 2009 B.A., Columbia University, 2002 His research focuses on the intersection of diabetes pharmacology , cardiovascular risk , and health services research . He has contributed extensively to understanding drug safety (e.g., sulfonylureas, SGLT2 inhibitors, TRK inhibitors), medication adherence , and clinical decision-making in diabetes and oncology settings. His methodological work includes instrumental variable analysis , pragmatic trial design , and real-world data validation . James Flory's recent publications examine temperature-related diabetes complications , AI in clinical decision support , and policy impacts on medication utilization . His work combines epidemiological methods with health informatics to address critical questions in diabetic care , drug safety surveillance , and health equity .

Struan F.A. Grantمشاهده پروفایل

استاد

• Human Genetics
• Pediatric Genomics
• Endocrinology
• +۵ مورد دیگر

Struan F.A. Grant is a distinguished Professor of Pediatrics (Human Genetics) at the University of Pennsylvania and a Professor of Genetics at the Perelman School of Medicine. He holds the Daniel B. Burke Endowed Chair for Diabetes Research and serves as Director of the Center for Spatial and Functional Genomics at Children's Hospital of Philadelphia (CHOP). His work bridges human genetics with pediatric disease genomics, focusing on obesity, diabetes, and bone disorders. Current affiliations: UPenn, CHOP Graduate group affiliations: Cell and Molecular Biology, Genomics and Computational Biology Research Focus : With over 25 years of experience, Grant's career highlights include discovering the COL1A1 polymorphic Sp1 site linked to osteoporosis and the TCF7L2 gene's role in type 2 diabetes. His current work leverages high-throughput genomics and bioinformatics to unravel pediatric disease mechanisms, particularly in obesity and metabolic disorders where genetic factors are more discernible due to limited environmental exposure. Scientific Awards : Wellcome Postdoctoral Fellowship Daniel B. Burke Endowed Chair for Diabetes Research Advising & Funding : Mentored numerous trainees including Max F. Dudek and Elizabeth A. Burton. Active funding includes grants from NIH (R01 HD056465, R01 HD100406, R01 AG072705, UM1 DK126194) and co-investigator roles in R01 NS135075, R01 AI154773, and P01 HL160471.

Kun Huangمشاهده پروفایل

استاد

• Biostatistics
• Genomics Data Sciences
• Precision Health
• +۳ مورد دیگر

Kun Huang is a Professor at Indiana University, serving as Chair of the Department of Biostatistics & Health Data Science within the School of Public Health . He holds multiple affiliations including Precision Health Initiative Professor of Genomics Data Sciences, Professor of Medicine, and Adjunct Professor positions in Medical & Molecular Genetics, Pharmacology & Toxicology, and Computer Science. Additionally, he is the Associate Director for Data Science at the IU Simon Comprehensive Cancer Center and an Investigator at the Regenstrief Institute. Dr. Huang specializes in Biostatistics , Genomics Data Sciences , and Precision Health , with a research focus on integrating multi-omics data and pathological images for cancer prognosis. His work in Machine Learning and Medical Imaging has led to innovative approaches in domain adaptation, batch correction, and multi-modal learning for biomedical applications. Recent publications highlight his expertise in single-cell RNA sequencing , neuroscience , and cancer genomics , with a recurring emphasis on data integration , computational modeling , and epigenetic regulation . His methodology explores deep transfer learning , multi-task learning , and gene co-expression networks across diverse contexts including aging-related neurodegeneration, cancer diagnostics, and neural circuit formation.

• Cancer Biology
• Hematology
• Developmental Genetics
• +۵ مورد دیگر

Martin H. Distel is a researcher affiliated with the Department of Pediatrics and the Hematology/Oncology Division . His work spans cancer biology, developmental genetics, and advanced imaging techniques in zebrafish models. PhD in Developmental Genetics, Technical University of Munich Postdoctoral Fellow, University of California, San Diego MSc and BSc, Technical University of Munich His research focuses on leveraging zebrafish models to study cancer mechanisms, including Ewing sarcoma and melanoma, and developing targeted therapies. He also investigates optical imaging technologies and their applications in oncology and neuroscience. Recent publications highlight work on drug screening in zebrafish xenografts, ROS-induced cancer cell targeting, and epigenetic regulation in tumors. His studies frequently employ high-content imaging and molecular biology approaches. Martin Distel contributes to preclinical testing of immunotherapies like CAR T-cells and has explored Notch signaling in hematopoietic stem cell differentiation. His interdisciplinary research bridges genetics, pharmacology, and biomedical engineering.